Financial news, mergers and acquisitions, partnerships, and alliances.
Yuhan Licenses HER2 Inhibitor From J INTS Bio in $325M Deal
J INTS Bio is evaluating JIN-A04 in preclinical studies as a treatment for HER2 exon 20-mutant non-small cell lung cancer.
Anew Medical Expecting to Access $54M Following SPAC Merger
The company is hoping the capital will help it advance a pipeline of gene therapies for various neurodegenerative diseases.
FDA Delays Decision for Sarepta Therapeutics Duchenne Muscular Dystrophy Gene Therapy
According to Sarepta, the federal agency has indicated it may grant accelerated approval to SRP-9001 as a treatment for a subgroup of patients based on age.
PTC Therapeutics Cuts Multiple Gene Therapy Programs
The company, which focuses on rare disease gene therapies and small molecule treatments, also said its CFO will leave the firm.
Checkpoint Therapeutics Announces $10M Registered Direct Offering of Common Stock
The company will use the funds to support the manufacturing and pre-commercial activities for its lead candidate cosibelimab.